Welcome to our dedicated page for LAVA Therapeutics N.V. Ordinary Shares news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics N.V. Ordinary Shares stock.
LAVA Therapeutics N.V. (Nasdaq: LVTX) is a pioneering biotechnology company that specializes in transforming cancer treatment through its innovative Gammabody® platform. This platform harnesses bispecific gamma-delta T cell engagers designed to target and eliminate cancer cells. The company focuses on both solid tumors and hematologic malignancies, aiming to deliver groundbreaking therapies for patients with unmet medical needs.
One of LAVA's lead programs is LAVA-1207, which targets the prostate-specific membrane antigen (PSMA) to treat metastatic castration-resistant prostate cancer (mCRPC). This program has shown a favorable safety profile and preliminary signs of anti-tumor activity in ongoing Phase 1/2a clinical trials across Europe and the United States. Recently, LAVA announced a collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate LAVA-1207 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
In addition to LAVA-1207, the company is advancing other promising candidates such as PF-08046052, formerly known as LAVA-1223, which targets EGFR-positive tumors and is being developed under a license agreement with Pfizer. LAVA is also preparing an IND submission for LAVA-1266, a treatment targeting CD123 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Financially, LAVA is well-positioned, with a focus on extending its cash runway into 2026 through strategic prioritization of its pipeline. The company has formed valuable collaborations, including partnerships with Seagen and Pfizer, to advance its clinical programs and support its growth trajectory.
For more detailed information on LAVA Therapeutics, visit their official website at www.lavatherapeutics.com and follow them on LinkedIn, X (formerly Twitter), and YouTube.
LAVA Therapeutics announced a strategic pipeline reprioritization focusing on LAVA-1266 for hematologic malignancies, while discontinuing LAVA-1207 development. The company will continue supporting partnered programs with Pfizer and Johnson & Johnson. Key Q4 developments include initiation of LAVA-1266 Phase 1 trial and a $5.0M milestone payment from J&J.
Financial highlights: Cash position of $78.9M as of September 30, 2024, with runway extended into 2027. Q3 2024 showed net losses of $12.3M ($0.46 per share) compared to $8.8M ($0.34 per share) in Q3 2023. Research and development expenses increased to $8.5M from $7.9M year-over-year.
LAVA Therapeutics (NASDAQ: LVTX), a clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Stephen Hurly, will present in a fireside chat format on Monday, September 9, 2024, at 3:30 PM ET.
LAVA Therapeutics specializes in developing the proprietary Gammabody® platform of bispecific gamma delta T cell engagers. Investors and interested parties can access a webcast of the presentation through the company's website under the 'Events' tab in the investor relations section. The replay will be available for 90 days after the presentation.
LAVA Therapeutics announced its Q2 2024 financial results and business updates. Major highlights include progress in the Phase 1/2a trial of LAVA-1207 for mCRPC, currently at dose level 12, with the pembrolizumab combination arm initiated. The next data update for LAVA-1207 is expected in Q4 2024. LAVA has a strong balance sheet with $86.8 million in cash, supporting operations into mid-2026. Financially, revenue for Q2 2024 was zero, down from $5.1 million in Q2 2023. R&D expenses decreased to $6.3 million, and G&A expenses to $3.0 million. Net loss improved to $8.3 million from $12.7 million in Q2 2023. The company also plans to initiate the Phase 1 trial of LAVA-1266 by year-end 2024 in Australia and received a $7 million milestone payment from Pfizer in Q1 2024.
LAVA Therapeutics (NASDAQ: LVTX), a clinical-stage immuno-oncology company, announced its participation in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. The event will be held on June 25, 2024, at 9:30 AM ET. Stephen Hurly, President and CEO of LAVA, will present a fireside chat focusing on the company's proprietary Gammabody® platform of bispecific gamma delta T cell engagers. The presentation can be accessed via webcast under the 'Events' tab on LAVA Therapeutics' investor relations website and will be archived for 90 days post-presentation.
LAVA Therapeutics N.V. (NASDAQ: LVTX), a clinical-stage immuno-oncology company specializing in its Gammabody® platform, announced its annual general meeting of shareholders. The meeting is scheduled for Wednesday, June 19, 2024, at 2:00 pm CEST. Shareholders can find all relevant documents and information, including the notice and agenda, in the “Investors” section of LAVA's website and on the SEC's website. To attend, shareholders must register as outlined in the provided notice and agenda.
LAVA Therapeutics, a clinical-stage immuno-oncology company, will participate in the Jefferies Global Healthcare Conference. Stephen Hurly, President and CEO, will represent the company in a fireside chat on June 5, 2024, at 8:00 a.m. ET. The discussion will be available via webcast on the company's investor relations website. The webcast replay will be archived for 90 days following the event. LAVA focuses on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers.
LAVA Therapeutics provided updates and financial results for Q1 2024. Key developments include the ongoing Phase 1/2a trial of LAVA-1207 for prostate cancer, with a pembrolizumab combination expected in Q2 2024. LAVA received a $7 million milestone payment from Pfizer for PF-08046052 in Phase 1 trials. LAVA-1266 is on track for Q2 2024 IND submission. Financially, LAVA reported $7 million in revenue for Q1 2024, up from $1.2 million in Q1 2023, with cash reserves at $94.6 million, providing a runway into 2026. The net loss improved to $0.5 million from $13.9 million in Q1 2023, mainly due to reduced R&D and administrative expenses.
LAVA Therapeutics N.V. (NASDAQ: LVTX) will participate in the Citizens JMP Life Sciences Conference where Stephen Hurly, President and CEO, will join a fireside chat. The event will take place on May 13, 2024, at 10:00 a.m. ET. The webcast can be accessed on the investor relations section of the LAVA Therapeutics website.
FAQ
What is the current stock price of LAVA Therapeutics N.V. Ordinary Shares (LVTX)?
What is the market cap of LAVA Therapeutics N.V. Ordinary Shares (LVTX)?
What is LAVA Therapeutics N.V.?
What is the Gammabody® platform?
What is LAVA-1207?
What recent achievements has LAVA Therapeutics made?
Who are LAVA Therapeutics' key partners?
Where are LAVA Therapeutics' clinical trials conducted?
What is PF-08046052?
What is the financial outlook for LAVA Therapeutics?
How does LAVA-1207 work?
Where can I find more information about LAVA Therapeutics?
